NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $895,058 | -18.0% | 1,273,379 | +163.7% | 0.01% | -35.0% |
| Q4 2022 | $1,091,370 | -28.0% | 482,907 | +1.9% | 0.02% | -31.0% |
| Q3 2022 | $1,516,000 | -18.1% | 473,751 | -2.7% | 0.03% | -43.1% |
| Q2 2022 | $1,850,000 | -8.4% | 486,724 | +29.9% | 0.05% | -5.6% |
| Q1 2022 | $2,020,000 | +759.6% | 374,700 | +2765.8% | 0.05% | +671.4% |
| Q3 2021 | $235,000 | -36.0% | 13,075 | -39.5% | 0.01% | -72.0% |
| Q4 2020 | $367,000 | -69.0% | 21,607 | -66.8% | 0.02% | -64.8% |
| Q3 2019 | $1,184,000 | – | 65,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |